The application of anthracyclines in anticancer therapy may result in accidental extravasation injury and can be a serious complication of their use. Tissue necrosis with skin ulceration is a possible outcome in the inadvertent extravasation of anthracyclines during intravenous administration. Until recently, there has been no effective treatment against the devastating effect of extravasated anthracycline. Preclinical and clinical studies are leading to the clinical implementation of dexrazoxane as the first and only proven antidote in anthracycline extravasation. In two multicenter studies dexrazoxane has proven to be highly effective in preventing skin necrosis and ulceration. This review focuses on the development and management of dexrazoxane in anthracycline extravasation injuries. © 2009 Jordan et al, publisher and licensee Dove Medical Press Ltd.
Jordan, K., Behlendorf, T., Mueller, F., & Schmoll, H. J. (2009). Anthracycline extravasation injuries: Management with dexrazoxane. Therapeutics and Clinical Risk Management. Dove Medical Press Ltd. https://doi.org/10.2147/tcrm.s3694